York Pharma


York Pharma acquires, develops and markets dermatology treatments. Its original product was Abasol, which had been developed up to phase III trials by a major European company, and is a treatment for fungal infections. York joined Aim on 26 April 2004, when it raised £1m gross (£735,000 net) via a placing and offer for subscription at 25p a share. It started out as a shell formed by Reverse Takeover Investments, a subsidiary of Aim-quoted Westside Acquisitions. In December 2004, it raised a further £2.8m at 80p a share. In early 2005, York bought Molecular Skincare for shares and it brought with it £2m in cash. It also expanded the range of products into eczema and psoriasis. In July 2005, sphingosine-1-phosphate, an acne treatment was acquired. In April 2007, York acquired Rosanto Pharmaceuticals for £2m in shares at a notional price of 123.7p a share. At the same time a placing at 120p a share raised £5.25m gross. In November 2007, York paid up to £17.5m in shares for Derms Development in order to benefit from its sales force in the UK and France. At the same time York raised £5.35m at 120p a share. In July 2008, York acquired Flammazine and Flammacerium from Solvay Pharmaceuticals for £22.6m. It was financed by loan notes and a £3.9m placing at 44p a share.

Sector: Health

News blog

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds